Endosonography followed by surgical staging improves quality of life, according to ASTER study
Patients who underwent endoscopic testing prior to surgery for lung cancer had significantly better quality of life at the end of the staging process, with no significant difference in costs between the two strategies, according to data presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC). "Given that assessment of lymph glands using the endoscopic approach was more effective, better tolerated by patients and no more expensive than the surgical approaches, we recommend that investigation should commence with the endoscopic tests, reserving the surgical tests as a backup if the endoscopic approaches do not show any evidence of cancer," said principal investigator Dr. Robert Rintoul of Papworth Hospital in Cambridge, United Kingdom. "We anticipate that this data will change the way in which the mediastinum is assessed in the future."
Before performing lung cancer surgery, it's important to determine whether the cancer has spread to the lymph glands in the middle of the chest, or mediastinum. If it has done so, then a surgical operation to attempt to remove the tumor may not be appropriate, Dr. Rintoul said.
Historically, biopsy of these lymph glands has required an exploratory surgical operation such as a mediastinoscopy. But new approaches to reach the lymph glands via the airway or the esophagus using flexible telescopes have been developed; these techniques are called endobronchial and endoscopic ultrasound.
Results of ASTER, a randomized clinical trial to compare the surgical biopsy approach with the endoscopic approaches, were published in the Journal of the American Medical Association in November 2010. They showed that assessing the lymph glands with the endoscopic approaches, using mediastinoscopy as a backup if the endoscopic approach did not show any evidence of cancer, was more effective than using mediastinoscopy alone.
At the end of staging, patients who underwent endosonography reported better quality of life than those randomized to surgical staging, researchers said at the World Conference on Lung Cancer. There was little difference between the two groups at 2 months and 6 months.
Mediastinal staging with endosonography was cost-effective compared with surgery alone, saving £746 (approximately $1,210 U.S./€845 euros) per patient. The savings rose to £2,124 (approximately $3,450 U.S./€2,400) per patient among those who had endosonography but did not undergo surgical staging.
Source: International Association for the Study of Lung Cancer
Articles on the same topic
- TEMLA shows higher diagnostic yield than EBUS or EUS in largest reported series to dateThu, 7 Jul 2011, 8:33:38 UTC
- Cancer patients with blood clots gain no benefit from adding IVCF to fondaparinuxThu, 7 Jul 2011, 8:33:16 UTC
- TGen presents lung cancer studies at Amsterdam conferenceThu, 7 Jul 2011, 7:33:39 UTC
- Canada's Cancer Risk Management model is an important new health tool for policymakersWed, 6 Jul 2011, 8:33:41 UTC
- Women, elderly, minorities poorly represented in lung cancer drug trial data submitted to US FDAWed, 6 Jul 2011, 8:33:31 UTC
- Elderly Dutch lung patients' survival improved by new treatment options between 2003-2009Wed, 6 Jul 2011, 8:33:06 UTC
- Increased investment in thoracic surgical expertise increased UK lung cancer resection rateWed, 6 Jul 2011, 8:32:53 UTC
- First whole-genome lung cancer study by TGen and Virginia G. Piper Cancer Center set for conferenceWed, 6 Jul 2011, 7:35:20 UTC
- Celecoxib may prevent lung cancer in former smokersWed, 6 Jul 2011, 4:33:12 UTC
- High EGFR expression a predictor for improved survival with cetuximab plus chemotherapy Tue, 5 Jul 2011, 9:02:35 UTC
- ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation ConsortiumTue, 5 Jul 2011, 9:02:25 UTC
- Lung tumors in never-smokers show greater genomic instability than those in smokersTue, 5 Jul 2011, 9:02:15 UTC
- EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapyTue, 5 Jul 2011, 9:02:06 UTC
- PET scan with [11C]erlotinib may provide noninvasive method to identify TKI-responsive lung tumorsTue, 5 Jul 2011, 9:01:57 UTC
Other sources
- Endosonography followed by surgical staging improves quality of life, according to new studyfrom Science DailyThu, 7 Jul 2011, 14:30:50 UTC
- TEMLA shows higher diagnostic yield than EBUS or EUS in largest reported series to datefrom PhysorgThu, 7 Jul 2011, 11:00:24 UTC
- Endosonography followed by surgical staging improves quality of life, according to ASTER studyfrom PhysorgThu, 7 Jul 2011, 11:00:22 UTC
- Cancer patients with blood clots gain no benefit from adding IVCF to fondaparinuxfrom PhysorgThu, 7 Jul 2011, 11:00:21 UTC
- TGen presents lung cancer studies at Amsterdam conferencefrom PhysorgThu, 7 Jul 2011, 8:01:37 UTC
- Celecoxib may prevent lung cancer in former smokersfrom Science DailyWed, 6 Jul 2011, 20:32:45 UTC
- Women, elderly, minorities poorly represented in lung cancer drug trial data submitted to US FDAfrom PhysorgWed, 6 Jul 2011, 14:30:50 UTC
- Canada's Cancer Risk Management model is an important new health tool for policymakersfrom PhysorgWed, 6 Jul 2011, 14:30:49 UTC
- Elderly Dutch lung patients' survival improved by new treatment options between 2003-2009from PhysorgWed, 6 Jul 2011, 14:01:53 UTC
- Increased investment in thoracic surgical expertise increased UK lung cancer resection ratefrom PhysorgWed, 6 Jul 2011, 14:01:45 UTC
- Celecoxib may prevent lung cancer in former smokersfrom PhysorgWed, 6 Jul 2011, 7:30:43 UTC
- First whole-genome lung cancer study set for conferencefrom PhysorgWed, 6 Jul 2011, 7:30:31 UTC
- Drug may prevent lung cancer in former smokersfrom Science BlogWed, 6 Jul 2011, 4:30:47 UTC
- ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortiumfrom Science DailyTue, 5 Jul 2011, 14:31:06 UTC
- Lung tumors in never-smokers show greater genomic instability than those in smokersfrom Science DailyTue, 5 Jul 2011, 14:31:05 UTC
- PET scan with [11C]erlotinib may provide noninvasive method to identify TKI-responsive lung tumorsfrom Science DailyTue, 5 Jul 2011, 14:31:04 UTC
- PET scan with [11C]erlotinib may provide noninvasive method to identify TKI-responsive lung tumorsfrom PhysorgTue, 5 Jul 2011, 9:00:23 UTC
- ALK rearrangement found in nearly 10 percent of patients in Lung Cancer Mutation Consortiumfrom PhysorgTue, 5 Jul 2011, 9:00:22 UTC
- Lung tumors in never-smokers show greater genomic instability than those in smokersfrom PhysorgTue, 5 Jul 2011, 9:00:22 UTC
- High EGFR expression a predictor for improved survival with cetuximab plus chemotherapyfrom PhysorgTue, 5 Jul 2011, 9:00:21 UTC
- EURTAC Phase III study: Erlotinib nearly doubles progression-free survival vs. chemotherapyfrom PhysorgTue, 5 Jul 2011, 9:00:20 UTC